Maria Lalioti

Maria Lalioti, Ph.D. Short bio
Maria Lalioti is a human molecular geneticist with a strong interest in personalized medicine and ethical
use of genomic information. She is the director of Pharmacogenomics at Biogen. Her responsibilities
include: assisting patient stratification into clinical trials based on their inherited mutations; using
genomics (Whole Genome Sequencing) and epigenomics (DNA methylation) to discover new disease
genes, mutations and biomarkers; and validating new drug targets. Biogen develops innovative
therapies for serious neurological diseases, including ALS, Multiple sclerosis, Alzheimer’s and Parkinson’s
disease, and has the only approved treatment for SMA. Before Biogen, she was an Assistant Professor in
the Dept. of Ob/Gyn at Yale University doing translational research in the genetics of ovarian
dysfunction and the director of the Preimplantation Genetic Diagnosis (PGD) program.
Dr Lalioti obtained her B.Sc. in Biology from the University of Athens, Greece and her M.Sc. and Ph.D.
degrees in Reproductive Biology and Human Genetics from the University of Geneva, Switzerland under
the mentorship of Prof. S. Antonarakis. She trained for her postdoc with Prof. Heath at the University of
Birmingham, UK and Prof. Lifton at Yale University. She was an EMBO and HSFP postdoctoral fellow and
has received numerous awards for her research including the Pfizer award in neuroscience, awards from
the American and European Societies of Human Genetics (ASHG and ESHG) and from the European
Society of Human Reproduction and Embryology (ESHRE). She is an assistant editor for Molecular
Human Reproduction.